Following the global call for action by the World Health Organization to eliminate cervical
cancer (CC), we evaluated how each CC policy decision in Norway influenced the timing of …

Background Human papillomavirus vaccine (HPV) impact on cervical precancer (cervical
intraepithelial neoplasia grades 2+[CIN2+]) is observable sooner than impact on cancer …

Background: To date, the impact of the human papillomavirus (HPV) vaccine on invasive
cervical cancers in the United States has not been documented due, in part, to the time …

Human papillomavirus (HPV) is the cause of almost all cases of cervical cancer, a disease
that kills some 340,000 women per year. The timeline from initial infection with HPV to the …

Background In the next 25 years, the epidemiology of cervical cancer in England, UK, will
change: human papillomavirus (HPV) screening will be the primary test for cervical cancer …

Cytology-based cervical screening appears to have had a limited effect on the incidence of
adenocarcinoma, however HPV vaccination and HPV-based screening will likely play a role …

Infection with high‐risk human papillomavirus (HR‐HPV) is transient and clears on its own in
majority of the women. Only a few women who have persistent infection may finally develop …

Background Cervical screening programs use testing for human papillomavirus (HPV)
genotypes. Different HPV types differ greatly in prevalence and oncogenicity. We estimated …

Objective Australia's HPV vaccination and HPV-based cervical screening programs are
changing the landscape in cervical cancer prevention. We aim to identify areas which can …

OBJECTIVES We aimed to quantify the temporal associations between cervical cancer
incidence and cervical cancer-related factors and to predict the number of new cervical …